ISDA

Deposition Date 2017-05-02

Release Date 2017-05-31

Last Version Date 2024-03-13

Entry Detail

PDB ID:

5VO6

Keywords:

TRANSFERASE/INHIBITOR

Title:

CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE INHIBITOR

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Spodoptera frugiperda

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.65 Å

R-Value Free:

0.28

R-Value Work:

0.20

R-Value Observed:

0.21

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Tyrosine-protein kinase JAK3
Gene (Uniprot):JAK3
Mutations:YES
Chain IDs:A
Chain Length:293
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P52333 Pfam ID:PF07714 EC:2.7.10.2

Ligand Molecules

9J4

Primary Citation

Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitors.

Hynes, J, Wu, H, Kempson, J, Duan, J.J, Lu, Z, Jiang, B, Stachura, S, Tokarski, J.S, Sack, J.S, Khan, J.A, Lippy, J.S, Zhang, R.F, Pitt, S, Shen, G, Gillooly, K, McIntyre, K, Carter, P.H, Barrish, J.C, Nadler, S.G, Salter-Cid, L.M, Fura, A, Schieven, G.L, Pitts, W.J, Wrobleski, S.T.Show

Bioorg. Med. Chem. Lett. 27 3101 3106 (2017)

PMID: 28539220 DOI: 10.1016/j.bmcl.2017.05.043

Abstact

A series of potent dual JAK1/3 inhibitors have been developed from a moderately selective JAK3 inhibitor. Substitution at the C6 position of the pyrrolopyridazine core with aryl groups provided exceptional biochemical potency against JAK1 and JAK3 while maintaining good selectivity against JAK2 and Tyk2. Translation to in vivo efficacy was observed in a murine model of chronic inflammation. X-ray co-crystal structure determination confirmed the presumed inhibitor binding orientation in JAK3. Efforts to reduce hERG channel inhibition will be described.

Legend

Protein

Chemical

Disease

Primary Citation of related structures